Thymoma Clinical Trial
Official title:
Evaluate the Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors
Verified date | September 2017 |
Source | Military Hospital 103 |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
the World Health Organization (WHO) has proposed a classification of histopathological thymic tumor and it significance in prognosis. Chest computed tomography (CT) is the most common method to evaluate thymic epithelial tumors before operation. Therefore, the question is to predict the histopathological type of thymic epithelial tumors before surgery based on CT-scan images , to help determine treatment strategy and prognosis. In Vietnam, there are no published literature on this issue.
Status | Completed |
Enrollment | 2 |
Est. completion date | July 31, 2017 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 71 Years |
Eligibility |
Inclusion Criteria: - All of patient have a chest CT scan pre-operation and a result of thymic epithelial tumors postoperative histopathology Exclusion Criteria: - Incomplete or loss the CT and postoperative histopathology |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Military Hospital 103 | Nguyen Truong Giang |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | maximun diameter of the tumor | Measure the maximun diameter of the tumor in chest CT scan | 1 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Terminated |
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 | |
Completed |
NCT00332969 -
Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma
|
Phase 2 | |
Completed |
NCT00921739 -
Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
|
Phase 1 | |
Recruiting |
NCT05255965 -
IL-8+ naïve T Cells as a Biomarker for Thymoma Identification
|
||
Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
Completed |
NCT00387868 -
Preoperative Treatment of Patients With High Risk Thymoma
|
Phase 2 | |
Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A | |
Recruiting |
NCT03466827 -
Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma
|
Phase 2 | |
Completed |
NCT02220855 -
A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
|
Phase 2 | |
Active, not recruiting |
NCT01242072 -
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
|
Phase 1 | |
Recruiting |
NCT06029621 -
Robot-assisted vs VATS for Thymoma
|
N/A | |
Active, not recruiting |
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 | |
Active, not recruiting |
NCT01621568 -
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
|
Phase 2 | |
Recruiting |
NCT05262582 -
Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy
|
N/A | |
Terminated |
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03968315 -
An Investigational Scan (MRI) in Imaging Patients With Newly-Diagnosed or Recurrent Thymoma
|
N/A | |
Recruiting |
NCT04162691 -
Single Cell Sequencing Analysis of Thymoma
|
||
Recruiting |
NCT06086327 -
Application of 68Ga-Pentixafor PET/CT for Thymoma
|
Early Phase 1 | |
Completed |
NCT01364727 -
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
|
Phase 2 |